These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31584494)

  • 21. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged response to
    Cottereau AS; Bricaire L; Arrondeau J; Dechmi A; Montravers F; Coriat R; Clerc J; Groussin L; Tenenbaum F
    Invest New Drugs; 2020 Aug; 38(4):1196-1199. PubMed ID: 31650444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application.
    Bal C; Yadav MP; Ballal S
    Clin Nucl Med; 2016 Aug; 41(8):e386-7. PubMed ID: 27187728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
    Zhang J; Kulkarni HR; Singh A; Baum RP
    Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
    Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
    Kalshetty A; Ramaswamy A; Ostwal V; Basu S
    Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual 177 Lu-Prostate-Specific Membrane Antigen and 177 Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation.
    Beyhan E; Erol Fenercioğlu Ö; Şahin R; Çermik TF; Ergül N
    Clin Nucl Med; 2024 May; 49(5):447-448. PubMed ID: 38409763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
    Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
    Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of a Prospective Phase 2 Pilot Trial of
    Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
    Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Hicks RJ; Jackson P; Kong G; Ware RE; Hofman MS; Pattison DA; Akhurst TA; Drummond E; Roselt P; Callahan J; Price R; Jeffery CM; Hong E; Noonan W; Herschtal A; Hicks LJ; Hedt A; Harris M; Paterson BM; Donnelly PS
    J Nucl Med; 2019 Jun; 60(6):777-785. PubMed ID: 30442752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
    Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
    Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vivo Instability of
    Lubberink M; Wilking H; Öst A; Ilan E; Sandström M; Andersson C; Fröss-Baron K; Velikyan I; Sundin A
    J Nucl Med; 2020 Sep; 61(9):1337-1340. PubMed ID: 32005767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of early oxidative stress following the use of radiotheranostics agents 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors; radioprotective effect of vitamin C.
    Jafari E; Ahmadzadehfar H; Bagheri D; Amini A; Assadi M
    Nucl Med Commun; 2021 Mar; 42(3):325-331. PubMed ID: 33306634
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
    Barna S; Haug AR; Hartenbach M; Rasul S; Grubmüller B; Kramer G; Blaickner M
    Clin Nucl Med; 2020 Sep; 45(9):661-667. PubMed ID: 32604113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
    Wei X; Schlenkhoff C; Sopora C; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Nov; 41(11):894-895. PubMed ID: 27607162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.